UroGen Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	188.73	109.79	90.4	82.71	64.36	48.04
Revenue Growth	100.27%	21.45%	9.29%	28.52%	33.96%	307.17%
Cost of Revenue	17.28	12.45	8.88	9.36	7.65	5.16
Gross Profit	171.46	97.34	81.52	73.35	56.7	42.89
Selling, General & Admin	176.85	155.1	120.05	93.27	82.84	87.54
Research & Development	61.26	67.11	57.15	45.61	52.91	47.64
Operating Expenses	238.11	222.2	177.2	138.89	135.74	135.18
Operating Income	-66.65	-124.86	-95.68	-65.54	-79.04	-92.29
Interest Expense	-16.22	-15.35	-12.52	-14.72	-8.44	-
Interest & Investment Income	3.96	5.97	8.9	2.64	0.94	0.37
Other Non Operating Income (Expenses)	-19.2	-19.17	-23.64	-20.71	-21.49	-17.44
EBT Excluding Unusual Items	-98.11	-153.42	-122.94	-98.32	-108.03	-109.37
Other Unusual Items	-	-	-1.1	-	-	-
Pretax Income	-98.11	-153.42	-124.04	-98.32	-108.03	-109.37
Income Tax Expense	-0.47	0.08	2.83	3.92	1.76	1.45
Net Income	-97.64	-153.49	-126.87	-102.24	-109.78	-110.82
Net Income to Common	-97.64	-153.49	-126.87	-102.24	-109.78	-110.82
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	49	48	43	29	23	22
Shares Outstanding (Diluted)	49	48	43	29	23	22
Shares Change	4.63%	12.22%	48.70%	26.43%	2.05%	2.60%
EPS (Basic)	-1.97	-3.19	-2.96	-3.55	-4.81	-4.96
EPS (Diluted)	-1.97	-3.19	-2.96	-3.55	-4.81	-4.96
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-159.14	-162.73	-97.06	-76.57	-87.81	-85.64
Free Cash Flow Per Share	-3.22	-3.38	-2.26	-2.66	-3.85	-3.83
Gross Margin	90.84%	88.66%	90.18%	88.68%	88.11%	89.27%
Operating Margin	-35.32%	-113.73%	-105.84%	-79.23%	-122.82%	-192.11%
Profit Margin	-51.73%	-139.81%	-140.35%	-123.61%	-170.58%	-230.67%
Free Cash Flow Margin	-84.32%	-148.22%	-107.37%	-92.57%	-136.45%	-178.27%
EBITDA	-66.35	-124.56	-95.35	-64.73	-78.12	-91.46
EBITDA Margin	-35.15%	-113.45%	-105.48%	-78.26%	-121.38%	-190.38%
D&A For EBITDA	0.31	0.31	0.33	0.8	0.92	0.83
EBIT	-66.65	-124.86	-95.68	-65.54	-79.04	-92.29
EBIT Margin	-35.32%	-113.73%	-105.84%	-79.23%	-122.82%	-192.11%

SEC Filings: 10-K · 10-Q